17 12

Cited 0 times in

Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial

Authors
 Kyung-Wan Min  ;  Bon Jeong Ku  ;  Ji-Hyun Lee  ;  Min-Seon Kim  ;  Kyu-Jeung Ahn  ;  Moon-Kyu Lee  ;  Satoshi Kokubo  ;  Satoshi Yoshida  ;  Hyun-Ji Cho  ;  Bong-Soo Cha 
Citation
 Diabetes & Metabolism Journal, Vol.41(4) : 135-145, 2017 
Journal Title
 Diabetes & Metabolism Journal 
ISSN
 2233-6079 
Issue Date
2017
Keywords
Asia ; Diabetes mellitus, type 2 ; Ipragliflozin ; Korea ; Metformin ; Randomized controlled trial ; Sodium-glucose cotransporter 2 inhibitor
Abstract
BACKGROUND: This is a subgroup analysis of Korean patients from a phase 3 clinical trial investigating the efficacy and safety of ipragliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin. METHODS: This multicenter, placebo-controlled, double-blind, parallel-group study was carried out between November 2011 and January 2013. Patients entered a 2-week placebo pretreatment period, followed by a 24-week treatment period with either ipragliflozin (50 mg/day) or placebo, while continuing metformin. Efficacy outcomes (glycosylated hemoglobin [HbA1c], fasting plasma glucose [FPG], and body weight) and safety outcomes (treatment-emergent adverse events [TEAEs]) were measured and compared between the two treatment groups for patients enrolled in all 18 study sites in Korea. RESULTS: Eighty-two Korean patients received ipragliflozin (n=43) or placebo (n=39) during the study period. Mean changes in HbA1c levels from baseline to the end of treatment were -0.97% in the ipragliflozin group and -0.31% in the placebo group, with an adjusted between-group difference of -0.60% (P<0.001). Compared to placebo, FPG and body weight also decreased significantly (both P<0.001) from baseline after treatment in the ipragliflozin group, with between-group differences of -21.4 mg/dL and -1.53 kg, respectively. Decreased weight was the most common TEAE in the ipragliflozin group (7.0%); there were no reports of genital and urinary tract infection. CONCLUSION: Ipragliflozin treatment in addition to metformin led to significant improvement in glycemic outcomes and reduction in body weight in Korean patients with type 2 diabetes mellitus, compared with metformin treatment alone; the safety profile was comparable in both groups.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/161155
DOI
10.4093/dmj.2017.41.2.135
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
차봉수(Cha, Bong Soo)
사서에게 알리기
  feedback
Files in This Item:
T201704194.pdf Download
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse